More than 2,300 Risperdal lawsuits are now pending in the Pennsylvania mass tort proceeding. Plaintiffs claim that Johnson & Johnson and its Janssen Pharmaceuticals unit concealed data linking Risperdal to gynecomastia, and failed to provide doctors and patients with appropriate warnings regarding this risk. They also claim that the companies wrongly marketed Risperdal for use in children long before U.S. regulators approved the drug for any pediatric indications.
So far, the majority of gynecomastia trials convened in Pennsylvania have ended with verdicts favoring plaintiffs. The most recent case that concluded in July with $70 million awarded to a teenager who experienced excessive breast growth shortly after he began taking the drug at the age of five. (Case No. No. 130402094)
The Pennsylvania litigation’s first gynecomastia trial ended in February 2015, with the jury awarding that plaintiff $2.5 million. (Case No. A-196444) A month later, another jury declined to award a second plaintiff any damages, after determining that there was not enough evidence to conclude that Risperdal had caused his breast growth. You may also take the advice from the risperdal gynecomastia lawsuits and clear your all doubts.
However, they did find that the safety warnings provided to patients and doctors were inadequate. (Case No. 130301803) In November 2015, a third gynecomastia plaintiff was awarded $1.75 million, although the Court later reduced the verdict to $680,000. (Case No. 130401990) A fourth Risperdal trial ended in December 2015 with a verdict for the plaintiff in the amount of $500,000. (Case No. 130401984)
Risperdal (risperidone), an antipsychotic indicated to treat Bipolar disorder (amongst other indications), was originally approved by the US Food and Drug Administration (FDA) in 1993 to treat schizophrenia in adults – although that indication was widened to include children in 2007.
Side effects of Risperdal can include Risperdal diabetes and related issues with Risperdal blood sugar, tardive dyskinesia (involuntary blinking, or movements of the tongue, mouth, face or limbs), and Risperdal stroke.
However, it remains Risperdal gynecomastia – the growing of male breasts – that has caught the majority of the attention. Various Risperdal gynecomastia lawsuits have alleged that adolescents and young males, with no history of weight issues or other factors exacerbated by an inactive lifestyle, are presenting with breast tissue following use of Risperdal for a period of time.